Table 1.
Data of the patients who underwent bronchoscopic IIT
| Case #, gender, age(years) | Location of lesion | AO (approx. %) | TEA nd/dd (mg) | EBB (n) | Histology |
|---|---|---|---|---|---|
|
Necrotic tumor (n = 8) | |||||
| 1 M(73) |
RMB |
80 |
250/120 |
10 |
SqCC |
| 2 M(41) |
RMB |
90 |
250/120 |
5 |
SqCC |
| 3 M(66) |
RB3 |
100 |
250/120 |
3 |
SqCC |
| 4 M(64) |
RLLB |
100 |
500/370 |
6 |
SqCC |
| 5 M(72) |
RBB |
100 |
500/370 |
3 |
SqCC |
| 6 M(58) |
RULB |
100 |
500/370 |
6 |
SqCC |
| 7 M(64) |
RULB |
90 |
500/370 |
5 |
AC |
| 8 M(80)* |
LMB |
100 |
500/370 |
5 |
MMT |
|
Hypervascular tumor (n = 12) | |||||
| 9 M(79) |
RBI |
70 |
250/120 |
4 |
SqCC |
| 10 M(58)* |
RMLB |
90 |
250/120 |
3 |
SCLC |
| 11 M(53) |
LULB |
100 |
500/370 |
4 |
SqCC |
| 12 M(61) |
LB4 |
80 |
500/370 |
5 |
SCLC |
| 13 M(47) |
RMB |
90 |
500/370 |
6 |
SqCC |
| 14 M(50) |
LULB |
50 |
500/370 |
7 |
AC |
| 15 M(62) |
RMB |
90 |
500/370 |
9 |
SqCC |
| 16 M(60) |
Trachea-LMB |
50-80 |
500/370 |
6 |
SqCC |
| 17 M(59) |
LULB |
80 |
500/370 |
6 |
SCLC |
| 18 M(64) |
RULB |
100 |
500/370 |
6 |
SqCC |
| 19 M(53) |
LULB |
50 |
500/370 |
7 |
SqCC |
| 20 M(67) | RBI | 60 | 500/370 | 7 | SqCC |
*Continuous dual antiplatelet therapy (aspirin and clopidogrel).
AC- adenocarcinoma; AO-airway obstruction; dd-approximate delivered dose; EBB-endobronchial forceps biopsy; LB4- superior lingular segmental bronchus; LMB- left main bronchus; LULB- left upper lobe bronchus; MMT- malignant mesenchymal tumor; nd-nominal dose; RBB-right basal bronchus; RBI- Right bronchus intermedius; RB3- right upper lobe anterior segmental bronchus; RLLB -right lower lobe bronchus; RMB - right main bronchus; RMLB-right middle lobe bronchus; RULB-right upper lobe bronchus; SCLC- small-cell lung carcinoma; SqCC- squamous cell carcinoma; TEA-tranexamic acid.